Company Reports

Recent Updates

All Reports

Company Report

With little direct competition in patch pumps for two decades, Insulet has been able to convert more users, especially patients on multiple daily injections, to its innovative, tubeless insulin pump. The firm has carved a path to meaningful profitability gains.
Company Report

With little direct competition in patch pumps for two decades, Insulet has been able to convert more users, especially patients on multiple daily injections, to its innovative, tubeless insulin pump. The firm has carved a path to meaningful profitability gains.
Company Report

With little direct competition in patch pumps, Insulet has been able to convert more users, especially patients on multiple daily injections, to its innovative, tubeless insulin pump. The firm has carved a path to meaningful profitability gains.
Stock Analyst Note

Insulet posted second-quarter revenue of $649 million, an increase of 31% in constant currency, with strong growth from both the US and international markets. Adjusted operating margin rose 670 basis points, driven primarily by lower sales and marketing expense.
Company Report

With little direct competition in patch pumps, Insulet has been able to convert more users, especially patients on multiple daily injections, to its innovative, tubeless insulin pump. The firm has carved a path to meaningful profitability gains.
Stock Analyst Note

Insulet posted strong second-quarter results that were generally consistent with our expectations. Though management raised its outlook, our full-year estimates remain bound by the new ranges, so we're leaving our $245 fair value estimate unchanged. Insulet demonstrated particularly strong quarterly top-line growth of 23% year over year. As the comparable periods become more challenging, we anticipate revenue growth to slow over the second half. This was the first period when Insulet faced the pressure from Tandem's new Mobi pump, and we are impressed with how well Insulet has withstood competitive conditions. This leaves us confident that Insulet's narrow economic moat and its underlying intangible assets are in good shape.
Stock Analyst Note

Insulet posted strong first-quarter results that generally met our expectations, and we’re holding steady on our fair value estimate. With this fast start to 2024, management has raised its outlook, and now our projections, which had previously extended beyond guidance, fall near the top end of management’s new range. We remain confident in Insulet’s narrow moat, which is supported by intangible assets. While quality of operations isn’t a generally a factor in how we assess durable moat sources, operations is a major strength of Insulet, in our view.

Sponsor Center